Poxel Sa Is A Clinical Stage Biopharmaceutical Company Based In Lyonfrancewith Additional Offices In Boston And Tokyofounded In 2009Poxel Is Dedicated To Developing Innovative Treatments For Chronic Diseases With Metabolic Pathophysiologyincluding Type 2 Diabetesnon Alcoholic Steatohepatitisnash And Rare Metabolic Disordersthe Company Is Listed On Euronext Paris Under The Ticker Poxel Poxel S Product Pipeline Features Several Key Candidatestwymeega Imegliminis Its Lead Productapproved In Japan For Type 2 Diabetes Treatment And Distributed By Sumitomo Pharmapxl065 Targets Nash And Has Shown Promising Results In Clinical Trialspxl770 Is An Ampk Activator Aimed At Treating Rare Diseases Such As Adrenoleukodystrophy And Autosomal Dominant Polycystic Kidney Diseasepoxel S Strategy Focuses On Expanding Its Pipeline And Forming Strategic Partnerships To Enhance Its Impact On Metabolic Diseases
No conferences found for this company.
| Company Name | Poxel Sa |
| Country |
France
|
| Address | N/A |
| Telephone | N/A |
| N/A |
